Key result
Eplerenone therapy over 24 months significantly improved left ventricular systolic strain in younger boys with Duchenne muscular dystrophy (median change -4.4%) while stabilizing function in older boys.
Why the study?
Does eplerenone improve LV systolic strain and maintain safety in boys with Duchenne muscular dystrophy and preclinical cardiomyopathy?
Population
11 boys with Duchenne muscular dystrophy and preclinical cardiomyopathy, median age 13 years.
Design
Cohort
Follow-up
24 months
Authors
Loading...
Supports eplerenone continuation in DMD cardiomyopathy; extends 12-month RCT data to 36 months with strain benefit in younger boys.
Does eplerenone improve LV systolic strain and maintain safety in boys with Duchenne muscular dystrophy and preclinical cardiomyopathy?
Absolute Event Rate: -4.4% vs 0.2%
p-value: p=0.0446
Long-term eplerenone therapy is safe and provides cardioprotection in boys with Duchenne muscular dystrophy, particularly when initiated at a younger age.
Raman et al. (2017) studied Duchenne muscular dystrophy cardiomyopathy (n=11). Eplerenone vs. Older subjects previously on eplerenone was evaluated on Change in left ventricular circumferential strain over 24 months (p=0.0446). Eplerenone therapy over 24 months significantly improved left ventricular systolic strain in younger boys with Duchenne muscular dystrophy (median change -4.4%) while stabilizing function in older boys.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: